PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 571 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Breaking News: The Healthcare Marketplace Re-opens TODAY! February 15, 2021 Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy... August 13, 2026 Breast Cancer Patient Given 2 Years to Live is Now a... May 28, 2021 Load more HOT NEWS 25-Year-Old Mom Had Chemo & Surgery, Then Was Told She Never... Partnering with Small Business to Advance Innovation in Cancer Research and... Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair
